We are live on
!
Find out more
BJCM
Blue Jay Capital Management Portfolio holdings
AUM
$147M
1-Year Est. Return
64.18%
This Fund
S&P 500
This Quarter
Est. Return
-8.1%
1 Year Est. Return
+64.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$156M
AUM Growth
-$140M
(-47%)
Cap. Flow
-$135M
Cap. Flow
% of AUM
-86.57%
Top 10 Holdings %
Top 10 Hldgs %
75.5%
Holding
31
New
8
Increased
4
Reduced
4
Closed
15
Top Buys
| 1 |
Ionis Pharmaceuticals
IONS
|
+$12.9M |
| 2 |
MJN
Mead Johnson Nutrition Company
MJN
|
+$12.4M |
| 3 |
Integra LifeSciences
IART
|
+$11.2M |
| 4 |
ABMD
Abiomed Inc
ABMD
|
+$10.4M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$6.61M |
Top Sells
| 1 |
Intuitive Surgical
ISRG
|
+$20.2M |
| 2 |
Edwards Lifesciences
EW
|
+$19.9M |
| 3 |
Biogen
BIIB
|
+$17.8M |
| 4 |
ENDP
Endo International plc
ENDP
|
+$15.6M |
| 5 |
BXLT
BAXALTA INC COM STK (DE)
BXLT
|
+$15M |
Sector Composition
| 1 | Healthcare | 84.17% |
| 2 | Consumer Staples | 9.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cooper Companies
COO
$14.3B
| $14.3M | 9.13% |
370,760
+10,760
| +3% | +$371K |
|
|
MJN
2
DELISTED
Mead Johnson Nutrition Company
MJN
| $14.1M | 9.04% |
+166,370
| New | +$12.4M |
|
3
Neurocrine Biosciences
NBIX
$17.1B
| $14.1M | 9.02% |
356,510
+156,450
| +78% | +$6.21M |
|
|
4
Ionis Pharmaceuticals
IONS
$8.94B
| $12.9M | 8.25% |
+318,490
| New | +$12.9M |
|
|
5
Integra LifeSciences
IART
$1.52B
| $12.1M | 7.75% |
+360,000
| New | +$11.2M |
|
|
ABMD
6
DELISTED
Abiomed Inc
ABMD
| $11.7M | 7.49% |
+123,590
| New | +$10.4M |
|
|
QGENF
7
DELISTED
QIAGEN NV
QGENF
| $10.6M | 6.79% |
475,000
+115,000
| +32% | +$2.57M |
|
|
STJ
8
DELISTED
St Jude Medical
STJ
| $10.5M | 6.69% |
190,140
+37,640
| +25% | +$2.05M |
|
9
Agilent Technologies
A
$38.1B
| $9.96M | 6.37% |
250,000
-35,000
| -12% | -$1.33M |
|
|
SHPG
10
DELISTED
Shire pic
SHPG
| $7.76M | 4.96% |
45,150
-46,880
| -51% | -$7.85M |
|
11
Quest Diagnostics
DGX
$23.6B
| $6.64M | 4.25% |
92,949
-82,211
| -47% | -$5.51M |
|
|
PDCO
12
DELISTED
Patterson Companies, Inc.
PDCO
| $6.63M | 4.24% |
+142,600
| New | +$6.18M |
|
|
MASI
13
DELISTED
Masimo
MASI
| $6.42M | 4.11% |
153,556
-61,444
| -29% | -$2.31M |
|
|
ALXN
14
DELISTED
Alexion Pharmaceuticals
ALXN
| $6.26M | 4.01% |
+45,000
| New | +$6.61M |
|
15
BioMarin Pharmaceuticals
BMRN
$11.6B
| $6.19M | 3.96% |
+75,000
| New | +$6.1M |
|
16
Incyte
INCY
$23.6B
| $6.16M | 3.94% |
+85,000
| New | +$6.33M |
|
|
ASRT
17
DELISTED
Assertio
ASRT
| – | – |
-8,917
| Closed | -$9.7M |
|
|
18
Biogen
BIIB
$31.6B
| – | – |
-58,161
| Closed | -$17.8M |
|
19
Bristol-Myers Squibb
BMY
$125B
| – | – |
-164,518
| Closed | -$11.3M |
|
|
20
Edwards Lifesciences
EW
$49.8B
| – | – |
-757,500
| Closed | -$19.9M |
|
|
HOLX
21
DELISTED
Hologic
HOLX
| – | – |
-325,747
| Closed | -$12.6M |
|
|
22
Intuitive Surgical
ISRG
$127B
| – | – |
-333,000
| Closed | -$20.2M |
|
23
Perrigo
PRGO
$1.56B
| – | – |
-65,600
| Closed | -$9.49M |
|
24
Vertex Pharmaceuticals
VRTX
$124B
| – | – |
-80,020
| Closed | -$10.1M |
|
|
NVRO
25
DELISTED
NEVRO CORP.
NVRO
| – | – |
-190,000
| Closed | -$12.8M |
|
Similar funds
BCM
RJA
RP
ACPVT
SFA
KL
KFS
FHC
Blue Jay Capital Management's Q1 2016 Portfolio in Review
As of Q1 2016, Blue Jay Capital Management held 31 positions worth $156M, down 47% from $297M the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Blue Jay Capital Management withdrew a net $135M in Q1 2016, closing 15 positions and reducing 4 holdings. Its most notable exit was Intuitive Surgical, an estimated $20.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier, followed by Consumer Staples.
Against the trend, Blue Jay Capital Management opened a new position in Ionis Pharmaceuticals worth $12.9M.
- Blue Jay Capital Management's largest Q1 2016 buy was Ionis Pharmaceuticals: 318,490 shares worth $12.9M.
- Blue Jay Capital Management added most to Neurocrine Biosciences in Q1 2016, an estimated $6.21M increase.
- Blue Jay Capital Management's biggest Q1 2016 reduction was Shire pic, cutting an estimated $7.85M.
- Blue Jay Capital Management fully exited Intuitive Surgical in Q1 2016, selling an estimated $20.2M.
- Blue Jay Capital Management's ten largest holdings make up 75% of its $156M portfolio in Q1 2016.
- Blue Jay Capital Management opened 8 new positions and closed 15 in Q1 2016.
- Blue Jay Capital Management's portfolio value fell 47% quarter-over-quarter to $156M.
Based on Blue Jay Capital Management's 13F filing for Q1 2016, filed 13 May 2016.